RELATED CONTENT
Advanced Accelerator Applications S.A. announced that its product NETSPOT (gallium Ga-68 dotatate) has been included in the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology version 1.2017 update for the evaluation of neuroendocrine tumors (NETs).
March 29, 2017 
September 16, 2014 — Advanced Accelerator Applications (AAA), an international specialist in molecular nuclear medicine, announced this week it has entered into an agreement with GE Healthcare in Italy to acquire its Italian FDG-PET imaging agent business (fluorodeoxyglucose positron emission tomography). This acquisition includes the license to market GE Healthcare’s SteriPET (FDG) imaging agent in Italy.
September 16, 2014 
Advanced Accelerator Applications, an international specialist in molecular nuclear medicine (MNM), announced it has entered into an agreement to acquire 100 percent of the shares of Imaging Equipment Ltd., a privately held U.K. distributor of nuclear medicine products and technologies.
March 06, 2014 March 4, 2014 — Advanced Accelerator Applications (AAA), a growing international player in molecular nuclear medicine, announced they have received orphan drug designation status for their radiopharmaceutical, Gallium-68 Dotatate.
March 04, 2014